Proteomics

Dataset Information

0

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection


ABSTRACT: Type I interferons (IFN-I) exert pleiotropic biological effects during viral infections, balancing virus control versus immune-mediated pathologies and have been successfully employed for the treatment of viral diseases. Humans express twelve IFN-alpha (α) subtypes, which activate downstream signalling cascades and result in distinct patterns of immune responses and differential antiviral responses. Inborn errors in type I IFN immunity and the presence of anti- IFN autoantibodies account for very severe courses of COVID-19, therefore, early administration of type I IFNs may be protective against life-threatening disease. Here we comprehensively analysed the antiviral activity of all IFNα subtypes against SARS-CoV-2 to identify the underlying immune signatures and explore their therapeutic potential. Prophylaxis of primary human airway epithelial cells (hAEC) with different IFNα subtypes during SARS-CoV-2 infection uncovered distinct functional classes with high, intermediate and low antiviral IFNs. In particular IFNα5 showed superior antiviral activity against SARS-CoV-2 infection. Dose-dependency studies further displayed additive effects upon co-administered with the broad antiviral drug remdesivir in cell culture. Transcriptomics of IFN-treated hAEC revealed different transcriptional signatures, uncovering distinct, intersecting and prototypical genes of individual IFNα subtypes. Global proteomic analyses systematically assessed the abundance of specific antiviral key effector molecules which are involved in type I IFN signalling pathways, negative regulation of viral processes and immune effector processes for the potent antiviral IFNα5. Taken together, our data provide a systemic, multi-modular definition of antiviral host responses mediated by defined type I IFNs. This knowledge shall support the development of novel therapeutic approaches against SARS-CoV-2.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung, Epithelial Cell

DISEASE(S): Covid-19

SUBMITTER: Thilo Bracht  

LAB HEAD: Thilo Bracht

PROVIDER: PXD026079 | Pride | 2022-02-09

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
HAE_SARS-CoV-2_Sample_Description.xlsx Xlsx
HAE_SARS-CoV-2_only_human_txt.7z Other
HAE_SARS-CoV-2_sdrf.tsv Tabular
HAE_SARS_CoV-2_w_o_MBR_txt.7z Other
QEXHF14643.raw Raw
Items per page:
1 - 5 of 65
altmetric image

Publications

Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.

Schuhenn Jonas J   Meister Toni Luise TL   Todt Daniel D   Bracht Thilo T   Schork Karin K   Billaud Jean-Noel JN   Elsner Carina C   Heinen Natalie N   Karakoese Zehra Z   Haid Sibylle S   Kumar Sriram S   Brunotte Linda L   Eisenacher Martin M   Di Yunyun Y   Lew Jocelyne J   Falzarano Darryl D   Chen Jieliang J   Yuan Zhenghong Z   Pietschmann Thomas T   Wiegmann Bettina B   Uebner Hendrik H   Taube Christian C   Le-Trilling Vu Thuy Khanh VTK   Trilling Mirko M   Krawczyk Adalbert A   Ludwig Stephan S   Sitek Barbara B   Steinmann Eike E   Dittmer Ulf U   Lavender Kerry J KJ   Sutter Kathrin K   Pfaender Stephanie S  

Proceedings of the National Academy of Sciences of the United States of America 20220201 8


Type I interferons (IFN-I) exert pleiotropic biological effects during viral infections, balancing virus control versus immune-mediated pathologies, and have been successfully employed for the treatment of viral diseases. Humans express 12 IFN-alpha (α) subtypes, which activate downstream signaling cascades and result in distinct patterns of immune responses and differential antiviral responses. Inborn errors in IFN-I immunity and the presence of anti-IFN autoantibodies account for very severe c  ...[more]

Similar Datasets

2021-11-28 | GSE189613 | GEO
2010-02-24 | E-GEOD-17400 | biostudies-arrayexpress
2010-12-01 | E-GEOD-22581 | biostudies-arrayexpress
2021-05-20 | GSE151513 | GEO
2021-05-25 | PXD022523 | Pride
2020-10-20 | PXD021685 | Pride
2023-01-19 | PXD037759 | Pride
2022-09-19 | GSE190672 | GEO
2022-08-05 | GSE182572 | GEO
2022-09-19 | GSE190673 | GEO